Breast cancer is a highly heterogeneous disease due to its diverse morphological features, the variable clinical outcome and the response to different therapeutic options. It is therefore necessary to devise a clinically meaningful classification of the disease, which has to be scientifically sound, clinically useful and widely reproducible. The established histopathological classification has a limited clinical utility, due to insufficient prognostic and predictive power. More recent classification schemes, based on the immunohistochemical characterization of breast cancer for the assessment of hormone receptor status, HER2 gene over-expression or amplification and the proliferative fraction or on gene expression profiles, correlate much better with the clinical outcome and may be used to inform the choice of the systemic therapy.
introduction
Breast cancer is unanimously considered a highly heterogeneous disease under several distinct viewpoints. Indeed, different types of this neoplasm exhibit variable histopathological and biological features, different clinical outcome and different response to systemic interventions. Based on such a high degree of heterogeneity, breast cancer cannot be viewed as a single clinico-pathological entity, but it must be necessarily dissected into a number of more homogeneous entities. Hence, it needs for a classification. As a general rule, a suitable classification of any disease has to be scientifically sound, clinically useful, easily applicable and widely reproducible. Unfortunately, and despite all the efforts in the past and in more recent years, the 'perfect' classification of breast cancer still has not been written. Herein, for the sake of clarity, the issue of breast cancer classification will be addressed with an historical perspective, from the more traditional histopathological subtypes to the newer molecular classes.
histopathological classification
The histopathological classification of breast carcinoma is based on the diversity of the morphological features of the tumors. In its current version, as endorsed by the WHO in 2003 [1] it includes some 20 major tumor types and 18 minor subtypes. This classification is adopted worldwide, it is reasonably reproducible and the residents in pathology learn how to apply it at the very beginning of their training.
A major drawback of this classification is that some 70%-80% of the all breast cancers will eventually belong to either one of the two major histopathological classes, namely invasive ductal carcinomas (IDCs) not otherwise specified (NOS) or invasive lobular carcinoma (ILC). This implies that the classification is unable to actually mirror the much wider heterogeneity of breast cancer, because it groups together, within the same class, tumors that have a very different biological and clinical profile. As a result, the histopathological classification has minimal prognostic and predictive implications, and its clinical utility is quite modest.
It is also debatable whether the two major classes of breast cancer, ductal and lobular, do actually reflect clinical differences, and whether ILC per se constitutes a prognostically favorable group, as previously suggested. In a large study of the International Breast Cancer Study Group on 9374 patients with pure IDC or ILC enrolled in 15 clinical trials with a median follow-up time of 13 years, ILC was associated with older age; larger, better differentiated and estrogen receptor (ER)-positive tumors; and less peritumoral vascular invasion [2] . There was a substantial early advantage in disease-free survival and overall survival for the ILC cohort followed by an important late advantage for the IDC cohort after 6 and 10 years, respectively. ILC was associated with an increased incidence of bone events but a decrease in regional and pulmonary metastases.
In a recent study, 301 consecutive ILCs of the 'classic' type seen at a single institution between 1994 and 2001 were compared with an equal number of IDCs, matched for the year of surgery, age, menopausal status, primary tumor size, nodal involvement, hormone receptor status and histological grade. There was no substantial difference in disease-free or overall survival, locoregional relapse or time to distant metastasis among the lobular and ductal groups overall or within any examined subset, although the lobular group showed a trend to earlier appearance of contralateral breast cancer [3] .
Interestingly, it is the correct identification of some minor tumor subtypes, the so-called 'special' tumor types, or of 'variants' of the main tumor types that may actually provide a clinically useful information, because these tumors have distinct prognostic profiles. This is the case, for example, of the tubular and cribriform carcinomas, pursuing an almost indolent clinical course with an extremely good overall survival [4] and of the adenoid-cystic carcinomas, carrying a very favorable prognosis in the vast majority of the cases [5] . Conversely, other subtypes of breast cancer, like the metaplastic carcinomas, may have a substantially worse clinical outcome than the IDCs NOS [6] . Furthermore, the differences in the clinical outcomes may be predicted by the identification of 'variant' subtypes among the ILCs. In a study of 530 patients with pure ILC (57% with the 'classic' type; 19% with the alveolar type; 11% with the solid type; and the remaining 13% characterized by pleomorphic, signet ring cell, histiocytoid or apocrine features), it has been shown that the 'classic' histotype of lobular carcinoma showed lower risk of axillary lymph node metastases, a reduced number of metastatic lymph nodes and lower tumor grade. Patients with the 'non-classic' variants of lobular carcinoma demonstrated a substantially increased risk for breast-related events and a trend toward reduced disease-free survival and overall survival [7] .
As a matter of fact, the histopathological classification remains an essential component of the pathological reports of breast cancer, together with tumor grade and stage (size of the invasive component and lymph node status). Importantly, the accurate identification of 'variant' and 'special' subtypes has prognostic implications and should not be dismissed.
biological classification to predict response to systemic interventions
In the last decade, a major effort has been done to better inform the choice of the systemic treatment for breast cancer patients. Risk assessment (e.g. tumor size and lymph node status) has been traditionally regarded as the main driver for the selection of the most appropriate therapy. More recently, however, this attitude has been challenged by the alternative option of relying on the expected responsiveness of the tumors to different therapeutic approaches, and then to fine tune the treatment according to the patients' risk. This has been best exemplified at the 2009 St. Gallen Consensus, with the panelists agreeing that the systemic therapy of early breast cancer is mainly informed by expression of hormone receptors and HER2 status [8] .
This peculiar 'classification' of breast cancer that may be best seen as a kind of working formulation for clinical use included three main classes, namely tumors considered to be highly endocrine responsive, those not endocrine responsive and the last group of tumors whose endocrine responsiveness remain uncertain. For patients with highly endocrine-responsive tumors, an endocrine treatment could be considered as the best therapeutic options; for those with non-endocrine-responsive tumors the only therapeutic option is the use of cytotoxic drugs (and trastuzumab in case of HER2 overexpression). Furthermore, for patients with ER-positive and HER2-negative disease, the option of adding chemotherapy to endocrine therapy is evaluated according to the tumor size, grade and proliferative fraction (most commonly assessed by immunohistochemical staining of the Ki67 antigen), occurrence of peritumoral vascular invasion, and nodal status.
It became therefore of primary importance for the systemic treatment of patients with early breast cancer to ensure the most accurate assessment of all these parameters in a reproducible and timely manner. In designing the systemic treatments, the treating physicians almost invariably have to completely rely on the data of the final pathological report, without any chance of verifying their accuracy.
The panelists of the 2009 St. Gallen Consensus took the seminal decision of defining ER-positive and progesterone receptor (PgR)-positive tumors showing 1% or more immunoreactive cells [8] . This definition has been subsequently endorsed by the expert panel issuing the ASCO/ CAP guideline recommendations for immunohistochemical testing of ER and PgR in breast cancer [9] . In case of ER or PgR-positive tumors, the actual percentage of neoplastic cells showing definite nuclear immunoreactivity must be reported, because the higher the number of positive cells the larger is the expected benefit of endocrine therapies. In addition to the actual percentage of the positive cells, it is recommended to report on the average intensity of the staining, whereas the use of a combined scoring system (like the H score or the Allred score) is considered optional.
Guidelines and recommendations describing how to optimally perform the immunohistochemical and in situ hybridization assays for assessing the HER2 status and evaluate and score the results have also been issued and recently updated [10, 11] . These assays have been clinically validated in several studies demonstrating the high predictive value of an HER2-positive status for the efficacy of HER2-targeted treatments. According to the regulatory agencies worldwide and the trastuzumab package insert, only patients whose tumors overexpress HER2 in more than 10% invasive tumor cells, or show HER2 gene amplification (four or more copies of the gene/cell, or a ratio ≥2 between the gene copy number and the chromosome 17 centromeres) are candidates to trastuzumab treatment.
Tumor proliferation is one of the most important prognostic parameters in breast cancer. In the clinical practice, the evaluation of the tumor proliferative fraction is most commonly performed by the immunohistochemical staining of the Ki67 antigen [12] . The use of Ki67 immunolabeling as a prognostic and predictive marker has been extensively investigated in both the neo-adjuvant and adjuvant settings [13, 14] . The panelists of the 2009 St. Gallen Consensus have included the assessment of Ki67 among the useful parameters to inform the choice of adding chemotherapy to endocrine therapies for patients with ER-positive and HER2-negative disease [8] . However, mainly due to the lack of standardization in the performance of the assay and in the interpretation and scoring of the results, the measurement of Ki67 has not been considered a useful prognostic marker in the updated recommendations for the use of tumor markers in breast cancers issued by ASCO in 2007 [15, 16] .
Certainly, to unveil the actual value of Ki67 as a prognostic and predictive marker in breast cancer, we have to improve standardization and reproducibility of its assessment. An ad hoc committee (the International Ki67 in Breast Cancer Working Group) has convened in London in March 2010 to share expertise and reach a consensus on the main technical and interpretative aspects of Ki67 immunolabeling, and to issue recommendations for an optimal testing [17] .
molecular classification
Due to the limited prognostic and predictive power of the existing classifications, at the beginning of the new century, new approaches have been considered to unveil the molecular basis for heterogeneity of breast cancer. By using a hierarchical clustering analysis of gene expression profiling, Perou et al. were able to identify molecularly defined classes of breast cancer (luminal, HER2-enriched, basal-like and normal-like) with distinctive biological and clinical features [18] [19] [20] . This molecular classification has been shown to have prognostic value and to be predictive of the response to chemotherapy in the setting [21] . The original molecular classification has been derived from investigations on fresh frozen tissue, and it is not applicable to formalin-fixed and paraffin-embedded (FFPE) material. This jeopardized the wide application of the new classification in the clinical practice. More recently, however, a gene expression assay using 50 genes (PAM50) has been developed for use on FFPE tissue. The assay, based on quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR), accurately identifies the major molecular subtypes of breast cancer and generates risk-of-relapse scores [22] . Its prognostic value has been confirmed in several retrospective investigations using tumor samples of patients with long-term follow-up data and of patients enrolled in randomized, clinical trials [23, 24] .
Another attempt to bring the molecular classification of breast cancer into the clinical practice has been to identify surrogate markers that would allow the identification of the molecular subtypes using the more familiar immunohistochemical approach. Accordingly, the combined evaluation of ER, PgR, HER2 and Ki67 immunoreactivity would approximate the molecular classification of luminal A, luminal B, HER2-enriched and basal-like breast cancers [25] . It should be noted, however, that the immunohistochemically and molecularly defined classes do not overlap completely. As an example, some basal-like breast cancers (according to the molecular classification) will not show the expected triplenegative (ER, PgR and HER2 negative) immunophenotype, and vice versa not all the immunohistochemically triplenegative breast cancer will be classified as basal-like by gene expression profiling [26] .
Despite the lack of complete overlapping among the molecular classes and their immunohistochemical surrogate, the panelists of the last St. Gallen Consensus have endorsed the use of the immunohistochemical assays to identify breast cancer subtypes and to inform the choice of the systemic treatments [27] . Interestingly, however, the panelists also warned to take into account some 'special' types of breast cancer of the more traditional histopathological classification, because these tumors, despite belonging to one of the abovedefined classes, most likely benefit from a different treatment.
epilogue Heterogeneity of breast carcinoma should not be viewed as an obstacle to a better understanding of the biology of the disease, or to the chances of designing more appropriate systemic treatments. On the contrary, heterogeneity may represent a tremendous opportunity for better tailoring the therapy of the patients. To achieve this goal, however, a general agreement on breast cancer classification should be reached. Unfortunately, for the time being, the 'perfect' classification is not available, and the ones described herein have all some merits and several limitations.
It is likely that the adoption of the clinically oriented classification endorsed by the St. Gallen panelists [27] may help to overcome the intrinsic limitations of the previous schemes, and prove to be effective in informing the choice of the systemic interventions. The proposed schema takes into account the modern concepts of the molecular classification of breast cancer, but endorses the use of the immunohistochemical surrogates, thus making the classification easily applicable in all the clinical settings. Furthermore, it does not ignore the usefulness of the precise identification of morphologically identifiable 'special' types of breast cancer, whose clinical outcome may be strikingly different from that of the other members of the same class, and justifies a different therapeutic option. Therefore, the current pathological report of breast carcinoma should include the histopathological classification of the tumors [1] and their histopathological grade, and the immunohistochemical parameters (ER, PgR, HER2 and Ki67) that would allow the treating physicians to tailor properly the systemic interventions.
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